Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Horatio Alger Honor Puts ResMed Leadership And Growth Story In Focus

2026-01-30
ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and medical devices. The award highlights ResMed's role in addressing sleep apnea and other respiratory conditions through its therapies and digital health tools. This recognition brings added attention to NYSE:RMD at a time when the company’s share price is $257.61. For investors following NYSE:RMD, this award puts a spotlight on the company’s long-term presence in sleep...

ResMed Q2 Earnings Call Highlights

2026-01-30
ResMed (NYSE:RMD) executives highlighted revenue growth, margin expansion and continued investment in product development and demand-generation initiatives during the company’s second quarter fiscal 2026 earnings call. Management also discussed progress in its software portfolio, the company’s view

ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations

2026-01-30
ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst competitive market dynamics.

ResMed (RMD) Q2 2026 Earnings Call Transcript

2026-01-29
Mick Farrell: Thank you, Sally, and good morning, good afternoon, good evening to all of our shareholders, and welcome to all to ResMed's second quarter fiscal year 2026 earnings call. For this March and the June quarters, we expect to continue our portfolio management process and maintain mid-single-digit growth across our RCS as we go through that portfolio management.

ResMed (RMD) Reports Q2 Earnings: What Key Metrics Have to Say

2026-01-29
The headline numbers for ResMed (RMD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ResMed (RMD) Q2 Earnings and Revenues Beat Estimates

2026-01-29
ResMed (RMD) delivered earnings and revenue surprises of +4.59% and +2.30%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

ResMed (NYSE:RMD) Exceeds Q4 CY2025 Expectations

2026-01-29
Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year to $1.42 billion. Its non-GAAP profit of $2.81 per share was 3.2% above analysts’ consensus estimates.

ResMed: Fiscal Q2 Earnings Snapshot

2026-01-29
SAN DIEGO (AP) — ResMed Inc. RMD) on Thursday reported fiscal second-quarter net income of $392.6 million. On a per-share basis, the San Diego-based company said it had net income of $2.68.

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

2026-01-29
Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE)

ResMed Inc. (RMD) Q2 2026 Earnings Call Transcript

2026-01-29